# Gustave Roussy account plan

> Gustave Roussy is a French comprehensive cancer centre in Villejuif with a 633 M€ budget, 4,000 employees and 24,000 new patients in 2025.

## At a glance

Gustave Roussy is a French comprehensive cancer centre (centre de lutte contre le cancer) in Villejuif, Val-de-Marne, combining care, research, education and technology transfer, with philanthropy run through the Gustave Roussy Fondation. It presents itself as first in France and in Europe by number of patients included in clinical trials. In 2025 it ran a 633 M€ budget (expenses of 633 M€ against income of 632 M€, two-thirds from hospital care), with 4,000 employees including 1,400 researchers and research staff, and 600 beds and places. It saw 24,000 new patients, 354,000 medical consultations and 144,000 stays. Its stated goal is to cure 80% of cancers by 2040.

## Business units

- **Care (Soins)** (66% of 2025 income (420 M€)): Hospital cancer care for adults and children: 24,000 new patients, 354,000 consultations and 19,500 operating-theatre interventions in 2025. Programmes include Interception (personalised early screening, ten centres being deployed in 2026) and Instadiag (rapid diagnosis, more than 2,000 patients in 2025). Paediatrics followed 2,800 patients.
- **Research** (Research contracts 15% (98 M€) and MERRI grant 7% (43 M€) of 2025 income): 41 research teams, 11 technology platforms, 1,389 publications and 7,505 patients included in 618 clinical studies in 2025. Includes the IHU PRISM precision-medicine institute and academic CAR-T cells deployed in 2025; Pr Fabrice André is Director of Research.
- **Philanthropy and Gustave Roussy Fondation** (Donations and legacies 7% of 2025 income (42 M€)): Total collection of 50.9 M€ in 2025 across the Institute and Foundation; the Foundation, chaired by Sébastien Bazin, collected 11.4 M€ and funds chairs of excellence and the future research building.
- **Gustave Roussy International**: Licenses the Gustave Roussy brand and model to cancer centres abroad: Egypt (opened April 2025), Uzbekistan (opened May 2026) and Kuwait (opening 2026). It also runs an alumni network of 2,000 members and an alliance with Dana-Farber Cancer Institute.
- **Gustave Roussy Transfert**: Technology transfer subsidiary led by Christophe Javaud with 110 patent families, 45 of them licensed, and an office in Boston; it works with Sofinnova Partners on start-up creation.
- **Gustave Roussy Education**: Initial and continuing education run with Université Paris-Saclay and 700 teachers; it is seeking Qualiopi certification in 2026 and launches a diploma in personalised cancer prevention from September 2026.

## Strategic priorities

- **Cure 80% of cancers by 2040**: The Projet d'établissement 2026-2030 keeps this goal and is built on four axes: individualised care pathways, high-impact research, resources matching ambitions, and digital and AI transformation.
- **High-impact research**: Reach 60 research teams by 2030 including 20 ERC-funded, include 1,000 patients in the DITEP early-trials department in 2030, lead at least two practice-changing trials a year and create an institute for cancers of young people.
- **Digital and AI transformation**: The information-systems budget doubled in two years; SI foundations are rebuilt in 2026, with DxCare, Chimio-Pharma and Doctolib in 2026, a move to Care4U in 2028-2030 and the GOLDEN health-data warehouse.
- **Double philanthropy**: Raise philanthropic collection to an annual target of 80 M€ by 2030, with 80% of collection dematerialised through a new AI-supported CRM.
- **Financial balance**: Keep a minimum self-financing capacity of 30 M€ a year on average over 2026-2030, with multi-year budget scenarios.
- **Early detection and individualised pathways**: Extend rapid diagnosis to all pathologies, scale up Interception and focus on key stages such as prevention, screening and initial treatment.

## Investments and deals

- **Cancer campus plan**: A 480 M€ investment plan over five years for what the report calls the largest cancer campus in Europe, with three new buildings in five years.
- **Research building**: A 33,000 m² building costing 190 M€ to host 60 research teams and 12 technology platforms, with delivery planned end 2028 / early 2029.
- **Education-office-parking and ambulatory buildings**: An education-office-parking building due in 2028 and a new ambulatory building for rapid diagnosis and Interception by the end of the plan.
- **Equipment and energy**: New heavy imaging and radiotherapy equipment and operating-theatre renovation are planned; 1.2 M€ invested in the heat network cut gas consumption by 42% versus 2024.

## Challenges and risks

- **Scarcer resources**: The plan is set in a context of accelerating innovation and scarcer resources; the Director General says research costs more and more and national cancer strategy funding remains relatively little.
- **Talent competition in Île-de-France**: Strong tension on health professions and competition for nurses, radiographers and IT/data talent; more than 100 nurses were recruited in 2025.
- **Thin financial balance**: 2025 expenses of 633 M€ slightly exceeded income of 632 M€ while the institution invests heavily in its campus.
- **Health sovereignty**: Barlesi warns that Europe and France risk dependence on the US and China if they cannot develop and manufacture some of their own drugs.
- **AI ethics and validation**: AI use in care and research requires human validation and ethics safeguards.

## What leadership says

> "What we want with this campus is to industrialise serendipity" — Pr Fabrice Barlesi, Director General, Kadans Oncology Summit, Paris, 4 June 2026 (Pharmaceutical Technology)

> "I believe that Europe and France are caught in the middle of two giants" — Pr Fabrice Barlesi, Director General, Kadans Oncology Summit, Paris, 4 June 2026 (Pharmaceutical Technology)

> "If we cannot develop at least some of the drugs we will need in the future, we risk becoming dependent on these two powers. We need to protect ourselves." — Pr Fabrice Barlesi, Director General, Kadans Oncology Summit, Paris, 4 June 2026 (Pharmaceutical Technology)


## Where a supplier can help

- **Clinical IT and data platforms**: Tied to the digital and AI priority: the DxCare-to-Care4U migration, the GOLDEN data warehouse and AI in record summaries and coding open room for software, integration and data suppliers.
- **Fundraising CRM and donor engagement**: Tied to the goal of 80 M€ of annual philanthropy by 2030 with an AI-supported CRM and 80% dematerialised collection.
- **Construction and campus equipment**: Tied to the 480 M€ campus plan: laboratory fit-out, heavy imaging, radiotherapy and building services for the research and ambulatory buildings.
- **Recruitment and retention**: Tied to the talent challenge: recruitment, training and employer-brand services for nurses, radiographers and IT/data profiles in Île-de-France.
- **Biotech and industry partnerships**: Tied to the sovereignty challenge and technology transfer: pharma, investors and manufacturing partners that help turn Gustave Roussy discoveries into therapies made in France.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Rapport annuel 2025 (Annual Report 2025)](https://www.gustaveroussy.fr/sites/default/files/documents/2026-10/rapport-annuel-2025-fr-08102026.pdf)

Annual report · 2026-10-08

- Gustave Roussy (Villejuif, Val-de-Marne) is a French comprehensive cancer centre combining care, research, education and technology transfer; it presents itself as first in France and in Europe by number of patients included in clinical trials.
- 2025 scale: 633 M€ of expenses against 632 M€ of income, 4,000 employees, 600 beds and places, 24,000 new patients, 354,000 medical consultations, 54,000 patients followed (2,800 in paediatrics) and 144,000 stays.
- Income mix 2025: care (hospital activity) 66% (420 M€), research contracts 15% (98 M€), MERRI grant 7% (43 M€), donations and legacies 7% (42 M€), other 5% (28 M€). Expenses: staff 45% (287 M€), medicines and other medical costs 35% (223 M€).
- Strategy: the Projet d'établissement 2026-2030 (built with nearly 1,000 staff) keeps the goal of curing 80% of cancers by 2040, around four axes: individualised care pathways, high-impact research, resources matching ambitions, and digital/AI transformation. The information-systems budget doubled in two years.
- Investment: a 480 M€ five-year plan for the cancer campus; a 33,000 m² research building (190 M€, 60 research teams, delivery end 2028 / early 2029) and an education-office-parking building due in 2028; a new ambulatory building in preparation.
- Research 2025: 1,389 publications (171 in journals with IF >= 30), 41 research teams, 11 technology platforms, 618 clinical studies and 7,505 patients included; academic CAR-T cells deployed in 2025; IHU PRISM precision-medicine institute.
- Philanthropy: total collection of 50.9 M€ in 2025 (13.4 M€ from legacies, donations and life insurance); Gustave Roussy Fondation (chair Sébastien Bazin) collected 11.4 M€ and funds chairs of excellence.
- Subsidiaries and growth levers: Gustave Roussy International (licensed centres in Egypt since April 2025, Uzbekistan since May 2026, Kuwait in 2026), Gustave Roussy Transfert (110 patent families, 45 licensed, Boston office), Gustave Roussy Education.
- Leadership: Pr Fabrice Barlesi (Director General), Pr Fabrice André (Director of Research), Dr Valérie Lapierre (CME President, cell therapy centre), Marie-Cécile Mocellin (HR), Marie-Claire Marty (nursing). Pressure points: scarcer resources, competition for nurses, radiographers and IT/data talent in Île-de-France.

### [Projet d'établissement 2026-2030](https://www.gustaveroussy.fr/sites/default/files/projet-etablissement-07012026.pdf)

Report · 2026-01-07

- Gustave Roussy's Projet d'établissement 2026-2030 (68 pages, January 2026) continues the 10-year Plan Stratégique Institutionnel begun in 2020, aiming to cure 15% more patients, i.e. 80%, within 15 years (by 2040).
- Four axes: deploy individualised care pathways; intensify research with strong societal impact; guarantee resources that match ambitions; accelerate digital transformation and AI deployment.
- Financial targets: keep a minimum self-financing capacity of 30 M€ a year on average over the period; double philanthropic collection to an annual target of 80 M€ by 2030, with 80% of collection dematerialised through a new AI-supported CRM.
- Research targets: 60 research teams by 2030 including 20 ERC-funded, 1,000 patients included in the DITEP early-trials department in 2030, at least two practice-changing trials a year, ten medico-scientific projects funded over five years, and a new institute for cancers of young people.
- Infrastructure: three new buildings in five years; Research and Education-Office-Parking buildings in service during 2028; a new ambulatory building (including rapid diagnosis and Interception) by the end of the plan.
- IT roadmap: SI foundations rebuilt in 2026; DxCare medical record, Chimio-Pharma and Doctolib in 2026; migration from DxCare to Care4U in 2028-2030; GOLDEN health-data warehouse; generative AI and AI agents for research.
- Growth levers: Gustave Roussy International moving to a modular licence offer (Egypt, Kuwait, Uzbekistan), Gustave Roussy Transfert adding financing and investment capabilities, Paris-Saclay Cancer Cluster service platforms (organoids, alpha-therapy, vectors) sold to industry and academia.

### [Cancer: "L'ambition est d'arriver à 80% de patients guéris en 2040" - Fabrice Barlesi on Public Sénat](https://www.publicsenat.fr/actualites/sante/cancer-lambition-est-darriver-a-80-de-patients-gueris-en-2040-projette-le-directeur-general-de-linstitut-gustave-roussy)

Executive talk · Fabrice Barlesi, Director General · 2026-02-05

- Pr Fabrice Barlesi, Director General of Gustave Roussy, interviewed on Public Sénat's morning show on 5 February 2026, the day after World Cancer Day.
- He restates the ambition of reaching 80% of patients cured in 2040, "on the path to a total cure of cancers within the century" (translated).
- Priorities to get there: continued investment in research, talent and drug development.
- He welcomes the State keeping the ten-year cancer strategy funding at the same level until 2030, but says the sum "remains unfortunately relatively little" (translated) given the missions it covers, and that research "costs more and more" (translated).
- Innovative treatments have a cost, all the more if France is not able to develop and manufacture them domestically: a health-sovereignty argument.
- Prevention: "We are rather bad at screening in France" (translated), although screening demonstrably reduces cancer mortality.
- He points to rising digestive cancers in young people and pancreatic cancer, and urges patients not to neglect any symptom.

### [Between two giants: Europe's new oncology chapter takes shape in Paris (Kadans Oncology Summit)](https://www.pharmaceutical-technology.com/newsletters/between-two-giants-europes-new-oncology-chapter-takes-shape-in-paris/)

Executive talk · Fabrice Barlesi, Chief Executive

- Pr Fabrice Barlesi, chief executive of Gustave Roussy, spoke at the inaugural Kadans Oncology Summit in Paris, held on 4 June for the opening of THE HIVE laboratory building at Campus Grand Parc next to Gustave Roussy (2026, as reported by Pharmaceutical Technology).
- His campus aim: "What we want with this campus is to industrialise serendipity," creating routine connections between scientists, entrepreneurs, clinicians and investors.
- He links Gustave Roussy's target of raising cancer cure rates to 80% by 2040 to the capacity to turn discoveries into commercially viable therapies that reach patients at scale.
- Three conditions he names: world-class scientific talent, entrepreneurs able to build companies around early breakthroughs, and enough capital and expertise to scale them into mature biotech businesses.
- Sovereignty warning: "I believe that Europe and France are caught in the middle of two giants" (the US and China); without developing some of its own drugs, Europe risks dependence.
- THE HIVE (developed by Kadans Science Partner) is presented as part of the answer: research institutions, start-ups, pharma and investors on one campus so discoveries are kept, scaled and commercialised at home.
- The Paris-Saclay Cancer Cluster selected 10 start-ups for the pilot of its BOOST Grant programme (€120,000 to €250,000 per project), including TheraSonic and One Biosciences.

## Questions about Gustave Roussy

### What is Gustave Roussy?

Gustave Roussy is a French comprehensive cancer centre in Villejuif that combines patient care, research, education and technology transfer. It presents itself as first in France and Europe by number of patients included in clinical trials.

### How big is Gustave Roussy?

In 2025 it had a 633 M€ budget, 4,000 employees, 600 beds and places, 24,000 new patients and 354,000 medical consultations.

### What is Gustave Roussy's strategy?

Its Projet d'établissement 2026-2030 aims to cure 80% of cancers by 2040 through individualised care pathways, high-impact research, secured resources and digital and AI transformation.

### Who leads Gustave Roussy?

Pr Fabrice Barlesi is Director General; Pr Fabrice André is Director of Research and Dr Valérie Lapierre is CME President.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
